Cargando…
Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial
BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA. METHODS: Three hundre...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015450/ https://www.ncbi.nlm.nih.gov/pubmed/29935544 http://dx.doi.org/10.1186/s12944-018-0797-2 |
_version_ | 1783334415792865280 |
---|---|
author | Hang, Yuanxing Qin, Xian Ren, Tianli Cao, Jianing |
author_facet | Hang, Yuanxing Qin, Xian Ren, Tianli Cao, Jianing |
author_sort | Hang, Yuanxing |
collection | PubMed |
description | BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA. METHODS: Three hundred seventy four patients with CAD and RA were randomized to receive either 500 mg baicalin or placebo orally everyday for 12 weeks. Lipid profile, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP), European League Against Rheumatism (EULAR) response were analyzed at the end of study period. RESULTS: After 12 week treatment, levels of triglycerides, total cholesterol, LDL-cholesterol and apolipoproteins, as well as CT-1 and hs-CRP, were all significantly improved in the baicalin group compared to the placebo group (1.12 ± 0.36 vs 1.87 ± 0.46 mmol/L, 2.87 ± 1.23 vs 3.22 ± 1.07 mmol/L, 1.38 ± 0.41 vs 1.16 ± 0.32 mmol/L, 1.31 ± 0.41 vs 1.23 ± 0.29 g/L, 42.9 ± 13.7 vs 128.4 ± 24.3 ng/mL, 1.64 ± 0.38 vs 3.9 ± 1.4 mg/dL, respectively). Significantly higher proportion of patients in the baicalin group (71%) reported good/moderate EULAR response than the placebo group (53%). CONCLUSION: Baicalin reduces blood lipids and inflammation in patients with both CAD and RA, supporting its further clinical application. |
format | Online Article Text |
id | pubmed-6015450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-60154502018-07-05 Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial Hang, Yuanxing Qin, Xian Ren, Tianli Cao, Jianing Lipids Health Dis Research BACKGROUND: Patients with rheumatoid arthritis (RA) have an increased risk of coronary artery disease (CAD) above the baseline. Baicalin possesses beneficial effects against both RA and CAD, but little is know on its clincial efficacy among patients manifesting both CAD and RA. METHODS: Three hundred seventy four patients with CAD and RA were randomized to receive either 500 mg baicalin or placebo orally everyday for 12 weeks. Lipid profile, cardiotrophin-1 (CT-1), high sensitivity C-reactive protein (hs-CRP), European League Against Rheumatism (EULAR) response were analyzed at the end of study period. RESULTS: After 12 week treatment, levels of triglycerides, total cholesterol, LDL-cholesterol and apolipoproteins, as well as CT-1 and hs-CRP, were all significantly improved in the baicalin group compared to the placebo group (1.12 ± 0.36 vs 1.87 ± 0.46 mmol/L, 2.87 ± 1.23 vs 3.22 ± 1.07 mmol/L, 1.38 ± 0.41 vs 1.16 ± 0.32 mmol/L, 1.31 ± 0.41 vs 1.23 ± 0.29 g/L, 42.9 ± 13.7 vs 128.4 ± 24.3 ng/mL, 1.64 ± 0.38 vs 3.9 ± 1.4 mg/dL, respectively). Significantly higher proportion of patients in the baicalin group (71%) reported good/moderate EULAR response than the placebo group (53%). CONCLUSION: Baicalin reduces blood lipids and inflammation in patients with both CAD and RA, supporting its further clinical application. BioMed Central 2018-06-23 /pmc/articles/PMC6015450/ /pubmed/29935544 http://dx.doi.org/10.1186/s12944-018-0797-2 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hang, Yuanxing Qin, Xian Ren, Tianli Cao, Jianing Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
title | Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
title_full | Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
title_fullStr | Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
title_full_unstemmed | Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
title_short | Baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
title_sort | baicalin reduces blood lipids and inflammation in patients with coronary artery disease and rheumatoid arthritis: a randomized, double-blind, placebo-controlled trial |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015450/ https://www.ncbi.nlm.nih.gov/pubmed/29935544 http://dx.doi.org/10.1186/s12944-018-0797-2 |
work_keys_str_mv | AT hangyuanxing baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial AT qinxian baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial AT rentianli baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial AT caojianing baicalinreducesbloodlipidsandinflammationinpatientswithcoronaryarterydiseaseandrheumatoidarthritisarandomizeddoubleblindplacebocontrolledtrial |